Health Services Research and Development Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
Department of Health Systems and Population Health, University of Washington School of Public Health, Seattle.
JAMA Netw Open. 2022 Jun 1;5(6):e2219651. doi: 10.1001/jamanetworkopen.2022.19651.
IMPORTANCE: Substance use disorders (SUDs) are major contributors to morbidity and mortality globally, but they are often underrecognized and underdiagnosed, particularly in some sociodemographic subgroups. Understanding the extent to which clinical diagnoses underestimate these conditions within subgroups is imperative to achieving equitable treatment, regardless of race, ethnicity, gender, or age, and to informing and improving performance monitoring. OBJECTIVE: To compare clinically documented diagnosis rates of alcohol use disorder (AUD), drug use disorder (DUD), and total SUD (AUD and/or DUD) with the prevalence of these disorders as reported in surveys-based on structured, validated diagnostic assessments-across demographic subgroups. DESIGN, SETTING, AND PARTICIPANTS: A telephone-based survey was conducted from January 8, 2018, to April 30, 2019, among 5995 Veterans Health Administration (VHA) outpatients who were randomly sampled from 30 VHA facilities and were 18 years of age or older, could complete the survey in English, and had a valid address and telephone number. Survey data were linked to electronic health record (EHR) data for all participants. Statistical analysis was performed between January 29, 2020, and April 20, 2021. EXPOSURES: Demographic subgroups based on self-report: gender (male or female), age (18-34, 35-49, 50-64, 65-74, and ≥75 years), and race and ethnicity (Black non-Hispanic, Hispanic, multiracial, other [Asian or Asian-American, American Indian or Alaskan Native, Native Hawaiian or Pacific Islander, and any other race endorsed by the participant], and White non-Hispanic). MAIN OUTCOMES AND MEASURES: Survey-based prevalence rates of AUD, DUD, and SUD were assessed using the Mini International Neuropsychiatric Interview, version 7.0, the only validated instrument available at study outset that measured Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria for past 12-month diagnoses. Clinically documented diagnosis rates were measured using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnoses from VHA EHR data. Analyses compared survey-based prevalence rates of AUD, DUD, and SUD with diagnosis rates using sensitivity and specificity and difference-in-difference analysis. All analyses were weighted with survey weights to account for nonresponse. RESULTS: Of 5995 participants, 4115 (68.6%) were White non-Hispanic, and 5429 (91.1%) were male; the mean (SD) age was 61.5 (15.3) years. The survey-based prevalence rates of AUD, DUD, and SUD were higher than the diagnosis rates among all patients (AUD, 608 [10.1%] vs 360 [6.0%]; DUD, 282 [4.7%] vs 275 [4.6%]; SUD, 768 [12.8%] vs 515 [8.6%]). Survey-based prevalence rates of AUD and SUD exceeded the diagnosis rates in every demographic subgroup. Gaps between diagnosis rates and survey-based prevalence rates for AUD and SUD were largest among patients aged 18 to 34 years (AUD diagnosis rate, 27 [6.9%; 95% CI, 4.8%-9.9%] vs AUD prevalence rate, 88 [22.4%; 95% CI, 17.3%-28.5%]; SUD diagnosis rate, 41 [10.5%; 95% CI, 8.1%-13.4%] vs SUD prevalence rate, 109 [27.7%; 95% CI, 22.6%-33.3%]) and Hispanic and Latinx patients (AUD diagnosis rate, 31 [7.6%; 95% CI, 5.3%-10.8%] vs AUD prevalence rate, 72 [17.7%; 95% CI, 14.0%-22.1%]; and SUD diagnosis rate, 48 [11.7%; 95% CI, 7.9%-16.9%] vs SUD prevalence rate, 88 [21.6%; 95% CI, 18.0%-25.8%]). For DUD, only patients aged 18 to 34 years had a true prevalence rate that significantly exceeded the diagnosis rate (diagnosis rate, 21 [5.4%; 95% CI, 3.7%-7.8%] vs prevalence rate, 40 [10.1%; 95% CI, 7.2%-14.0%]). CONCLUSIONS AND RELEVANCE: The results of this survey study suggest that existing diagnostic procedures and tools are insufficient to capture SUD prevalence rates, particularly among younger patients and Hispanic and Latinx patients. Clinics and health systems should implement standardized SUD assessments to ensure the provision of equitable care and the optimal identification of underlying conditions for performance monitoring.
重要性:物质使用障碍(SUD)是全球发病率和死亡率的主要原因,但它们经常被低估和漏诊,特别是在某些社会人口亚组中。了解临床诊断在亚组内低估这些疾病的程度对于实现公平治疗至关重要,无论种族、民族、性别或年龄如何,并为绩效监测提供信息和改进。 目的:将基于结构化、经过验证的诊断评估的调查中报告的酒精使用障碍(AUD)、药物使用障碍(DUD)和总 SUD(AUD 和/或 DUD)的流行率与基于临床记录的诊断率进行比较,这些亚组跨越了人口统计学亚组。 设计、地点和参与者:2018 年 1 月 8 日至 2019 年 4 月 30 日期间,通过电话对 30 个 VHA 设施中随机抽取的 5995 名 VHA 门诊患者进行了一项基于调查的调查,这些患者年龄在 18 岁或以上,能够用英语完成调查,并且有有效的地址和电话号码。对所有参与者进行了电子健康记录(EHR)数据的链接。统计分析于 2020 年 1 月 29 日至 2021 年 4 月 20 日进行。 暴露:基于自我报告的人口统计学亚组:性别(男性或女性)、年龄(18-34、35-49、50-64、65-74 和≥75 岁)和种族和民族(黑人非西班牙裔、西班牙裔、多种族、其他[亚裔或亚裔美国人、美国印第安人或阿拉斯加原住民、夏威夷原住民或太平洋岛民以及参与者认可的任何其他种族]和白人非西班牙裔)。 主要结果和测量:使用迷你国际神经精神访谈,第 7.0 版,评估基于调查的 AUD、DUD 和 SUD 的流行率,这是研究开始时唯一可用的经过验证的工具,可测量过去 12 个月的诊断标准。使用 VHA EHR 数据中的国际疾病分类和相关健康问题,第 10 版诊断,测量临床记录的诊断率。使用敏感性和特异性以及差异分析比较基于调查的 AUD、DUD 和 SUD 流行率与诊断率。所有分析均使用调查权重进行加权,以考虑无应答情况。 结果:在 5995 名参与者中,4115 名(68.6%)是白人非西班牙裔,5429 名(91.1%)是男性;平均(SD)年龄为 61.5(15.3)岁。AUD、DUD 和 SUD 的基于调查的流行率高于所有患者的诊断率(AUD,608[10.1%] vs 360[6.0%];DUD,282[4.7%] vs 275[4.6%];SUD,768[12.8%] vs 515[8.6%])。在每个人口统计学亚组中,基于调查的 AUD 和 SUD 的流行率都高于诊断率。AUD 和 SUD 的诊断率与基于调查的流行率之间的差距在 18 至 34 岁的患者中最大(AUD 诊断率,27[6.9%;95%CI,4.8%-9.9%] vs AUD 流行率,88[22.4%;95%CI,17.3%-28.5%];SUD 诊断率,41[10.5%;95%CI,8.1%-13.4%] vs SUD 流行率,109[27.7%;95%CI,22.6%-33.3%])和西班牙裔和拉丁裔患者(AUD 诊断率,31[7.6%;95%CI,5.3%-10.8%] vs AUD 流行率,72[17.7%;95%CI,14.0%-22.1%];SUD 诊断率,48[11.7%;95%CI,7.9%-16.9%] vs SUD 流行率,88[21.6%;95%CI,18.0%-25.8%])。对于 DUD,只有 18 至 34 岁的患者有一个真正的流行率显著高于诊断率(诊断率,21[5.4%;95%CI,3.7%-7.8%] vs 流行率,40[10.1%;95%CI,7.2%-14.0%])。 结论和相关性:这项调查研究的结果表明,现有的诊断程序和工具不足以捕捉 SUD 的流行率,特别是在年轻患者和西班牙裔和拉丁裔患者中。诊所和卫生系统应实施标准化的 SUD 评估,以确保提供公平的护理,并为绩效监测提供潜在疾病的最佳识别。
Cochrane Database Syst Rev. 2022-2-1
JAMA Netw Open. 2025-4-1
JAMA Netw Open. 2025-3-3
Am J Prev Med. 2025-3
Am J Psychiatry. 2024-11-1
Drug Alcohol Depend. 2021-8-1
Drug Alcohol Depend. 2020-11-1
J Public Health Manag Pract. 2020
Alcohol Clin Exp Res. 2020-1